Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis

Author:

Njire Moses12,Wang Na13,Wang Bangxing1,Tan Yaoju4,Cai Xingshan4,Liu Yanwen4,Mugweru Julius12,Guo Jintao1,Hameed H. M. Adnan12,Tan Shouyong4,Liu Jianxiong4,Yew Wing Wai5,Nuermberger Eric6,Lamichhane Gyanu6ORCID,Liu Jinsong12,Zhang Tianyu12ORCID

Affiliation:

1. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

2. University of Chinese Academy of Sciences, Beijing, China

3. School of Life Science, University of Science and Technology of China, Hefei, China

4. State Key Laboratory of Respiratory Disease, Department of Clinical Laboratory, Guangzhou Chest Hospital, Guangzhou, China

5. Stanley Ho Centre for Emerging Infectious Diseases, the Chinese University of Hong Kong, Hong Kong, China

6. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Abstract

ABSTRACT Pyrazinamide (PZA), an indispensable component of modern tuberculosis treatment, acts as a key sterilizing drug. While the mechanism of activation of this prodrug into pyrazinoic acid (POA) by Mycobacterium tuberculosis has been extensively studied, not all molecular determinants that confer resistance to this mysterious drug have been identified. Here, we report how a new PZA resistance determinant, the Asp67Asn substitution in Rv2783, confers M. tuberculosis resistance to PZA. Expression of the mutant allele but not the wild-type allele in M. tuberculosis recapitulates the PZA resistance observed in clinical isolates. In addition to catalyzing the metabolism of RNA and single-stranded DNA, Rv2783 also metabolized ppGpp, an important signal transducer involved in the stringent response in bacteria. All catalytic activities of the wild-type Rv2783 but not the mutant were significantly inhibited by POA. These results, which indicate that Rv2783 is a target of PZA, provide new insight into the molecular mechanism of the sterilizing activity of this drug and a basis for improving the molecular diagnosis of PZA resistance and developing evolved PZA derivatives to enhance its antituberculosis activity.

Funder

Guangzhou Medical University (GMU) China

University of Chinese Academy of Sciences

National Natural Science Foundation of China

Chinese Academy of Sciences

Guangzhou Science and Technology Program key projects

Guangdong Science and Technology Department

Ministry of Science and Technology of the People's Republic of China and National Health Family Planning Commission of the People's Republic of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3